摘要
目的:观察吉西他滨联合顺铂二线治疗晚期非小细胞肺癌的疗效及毒性反应.方法:从2000年3月～2004年10月对38例晚期非小细胞肺癌患者采用二线化疗,入组患者均经病理组织学证实,有可测量病灶,具体为吉西他滨1 000mg/m2第1、8天,顺铂80mg/m2,分3天应用,21天为1个周期.化疗2个周期后评价疗效及毒副反应.结果:所有患者均可评价,总共进行108周期的化疗.完全缓解(CR)0例,部分缓解(PR)11例,稳定(SD)12例,进展(PD)15例,总有效率28.9%.中位缓解时间4.5月,中位生存时间7.8月.主要不良反应为血液学毒性,其中Ⅲ/Ⅳ度的中性粒细胞下降、血小板下降和血红蛋白下降分别为18.5%(20/108)、11.1%(12/108)和8.3%(9/108).其次为消化道毒性,Ⅲ/Ⅳ度的食欲下降和恶心呕吐分别为13.9%(15/108)和12.0%(13/108).结论:吉西他滨联合顺铂对复治晚期非小细胞肺癌有较好疗效,毒副反应可以耐受.
Objective：To investigate the efficacy and toxicity of gemcitabine combined with cisplatin as second-line chemotherapy for patients with advanced NSCLC. Methods： From March 2000 to October 2004, 38 evaluable patients with advanced NSCLC after failure to first-line platinum based chemotherapy received gemcitabine （1 000 mg/m^2 ivgtt） on days 1, 8 and cisplatin （80mg/ m^2, ivgtt） on clays 1 to 3 the regimen repeated every 3 weeks and the efficacy and toxicity were evaluated after 2 cycles according RECIST criteria. Results ：The efficacy and toxicity of 108 cycles for group were assessed. Objective response rate （CR＋PR=0＋11 ） was 28.9% （ 11/38 ） , Median remission time was 4. 5 months and the median survival time was 7.8 months. Grades 3/4 of neutropenia, thrombocytopenia and anemia were 18.5% （20/108） , 11.1% （12/108） and 8.3% （9/108）. Grades 3/4 of anorexia and nausea/vomiting were observed in 13.9% （15/108） and 12.0% （13/108） of patients, respectively. Conclusion：We suggest that, as a selective second-line chemotherapy, this regimen is efficacious and tolerable for previous treated patients with NSCLC.
出处
《临床肿瘤学杂志》
CAS
2005年第6期593-595,共3页
Chinese Clinical Oncology
关键词
非小细胞肺癌
二线化疗
吉西他滨
顺铂
Non-small cell lung cancer
Second-line chemotherapy
Gemcitabine
Cisplatin
